Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 549

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 549
---
                     ​                        ​      ​      ​    ​    ​       ​      ​    ​    ​       ​      ​    ​ 
---------------------------------------------------------------------------------------------------------------------
​                                             ​                                               Year Ended December 31,
​                                             ​                2024    ​                2023    ​                2022
​                                                   $’000         %          $’000         %          $’000         %
Revenue—Other Ventures                                                                                               
Prescription drug products                        262,850      98.5        295,396      95.5        237,293      90.4
Healthcare products (incl. consumer health)         3,986       1.5         13,987       4.5         25,272       9.6
Total                                             266,836     100.0        309,383     100.0        262,565     100.0
​
Revenue from our Other Ventures primarily comprises revenue from prescription drugs including the commercial services, logistics and distribution business of our consolidated Distribution Business joint venture with Sinopharm, a leading distributor of pharmaceutical products and a leading supply chain service provider in China. 
Revenue from our Other Ventures also comprises revenue from sales of Zhi Ling Tong infant nutrition and other health supplement products manufactured by Hutchison Healthcare and distributed through our Distribution Business up until the end of September 2022 and through Shanghai Hutchison Pharmaceuticals, our non-consolidated joint venture from October 1, 2022 onwards, organic and natural products by Hutchison Hain Organic (which was divested in December 2023), and certain third-party consumer products distributed and marketed by HUTCHMED Science Nutrition (which was divested in December 2023).
​

The revenue of our non-consolidated joint venture, Shanghai Hutchison Pharmaceuticals, the accounts of which are prepared in accordance with IFRS as issued by the IASB and whose revenue is not included in our consolidated revenue, was $370.6 million, $385.5 million and $393.5 million for the years ended December 31, 2022, 2023 and 2024, respectively. Shanghai Hutchison Pharmaceuticals is a joint venture with Shanghai Pharmaceuticals, a leading pharmaceuticals company in China, and primarily focuses on the manufacture and sale of prescription pharmaceutical products in China. We and Shanghai Pharmaceuticals each own 50% of this joint venture. We have the right to nominate the general manager and other management of this joint venture and run